A Pragmatic Randomized-Controlled Learning Health System Trial of mPATH-Lung A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients

What this Trial Is About

Researchers are evaluating the real-world effectiveness of mPATH-Lung, a mobile patient health technology, in increasing lung cancer screening rates among diverse populations. This pragmatic, randomized controlled trial focuses on engaging racial/ethnic minorities and rural residents within an academic Learning Health System. The study aims to compare different outreach strategies and assess additional revenue from increased screenings, as well as potential over-screening effects. Participants will be randomly assigned to one of four groups: receiving a portal message followed by up to three reminder text messages, receiving text messages only with reminders, receiving a portal message only without reminders, or receiving usual care. Reminder messages vary depending on whether participants have upcoming appointments, with messages timed around appointments and program engagement. During the study, participants' lung cancer screening completion within 90 days will be tracked, along with eligibility, screening requests, and orders. Researchers will also evaluate revenue generated within 12 months and monitor potential over-screening. The involvement includes use of patient portals or cellphones for messaging, and data collection occurs through electronic health records and follow-up over time. The study enrollment is for patients aged 50 to 77 years with specific smoking histories and healthcare engagement requirements.

A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients